Business Context and Reporting Period
Company: Belite Bio, Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2026 (Specific event date: April 21, 2026)
Belite Bio, Inc. filed this report to disclose a significant corporate development regarding its lead drug candidate, Tinlarebant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is an event-driven disclosure and does not contain financial statements or quantitative financial data.
Material Changes
- Regulatory Milestone: On April 21, 2026, the company initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
- Indication: The NDA is for Tinlarebant for the treatment of Stargardt Disease.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release detailing the NDA submission. No specific financial guidance, revenue outlook, or quantitative risk factors are provided in this document.
Unusual Items: None reported beyond the standard regulatory filing of the NDA.
Investor Verification Checklist
- Verify the status and timeline of the FDA review for the Tinlarebant NDA.
- Confirm the specific data package submitted for Stargardt Disease treatment.
- Review the attached Exhibit 99.1 (Press Release) for detailed clinical trial results supporting the submission.
- Monitor subsequent filings for any FDA responses or requests for additional information.